It has launched a transfection reagent for in vivo mRNA delivery using a preformed liposome to further support the growing demand of mRNA developers. It says its in-vivo-jetRNA+ supports in vivo mRNA delivery with liposomes and offers an alternative to lipid nanoparticles (LNPs).
mRNA delivery using in vivo-jetRNA+ can be used for vaccination purposes, anti-cancer studies, genome editing using CRISPR/Cas9 method or protein replacement. The transfection reagent can be used to target unique or multiple organs, by using systemic injection routes, in various animal models including mice and rats.
“LNP technology, which is for the mRNA vaccines currently on the market, is an intensive process. Our in vivo-jetRNA+ come ready-to-use with a two-step protocol. A highly efficient formulation offers up to 100% mRNA encapsulation and the in vivo-jetRNA+ and mRNA liposomes are stable over time, unlike LNPs, which are extremely sensitive,” a spokesperson for the company told us.
The protocol involves the mixing of the mRNA with the transfection reagent, then the resulting solution is injected into the animals.
“There is no need for formulation, extra equipment, or to create a new recipe for each mRNA. In addition, the process is readily translatable to larger scale due to the stability of the liposomes. Consequently, in vivo-jetRNA+ is ideal for use in proof-of-concept studies. Furthermore, the liposomes formed using in vivo-jetRNA+ remain stable over time for both low and high mRNA concentrations, enabling its employment for many different applications and injection routes,” added the spokesperson.